EGFR and lung cancer: This clonal heterogeneity may explain both the “flare” phenomenon (rapid tumor regrowth upon withdrawal of an EGFR TKI) observed in EGFR mutant lung cancer patients upon discontinuation of an EGFR TKI and also the finding that patients may respond to subsequent EGFR TKI treatment after initial discontinuation of therapy.